BACH1 Pathway Metastasis Signature for Triple Negative Breast Cancer



    • Triple negative breast cancer (TNBC) patients are a clinically underserved group, with fewer therapy options available compared to other breast cancer patients and poorer survival statistics. Current breast cancer diagnostics are limited in resolution with TNBC patients, and as such, clinicians need additional tools to evaluate them.
    • The inventors identified 30 genes that are downstream of the metastasis regulator, BACH1. These genes can stratify patients with the most lethal forms of TNBC.
    • The invention is a prognostic gene signature for predicting relapse free survival in TNBC breast cancer patients. This gene signature can be used with pre-existing diagnostic kits to boost the resolution of patient stratification.
    • The gene signature was validated in a retrospective cohort (n=1600) of breast cancer patients. 10-20% of patients predicted to have good prognosis by FDA approved diagnostics were shown to have poor prognosis by the BACH1 supplemental gene signature.



    Patients were screened and determined (A) by Mammaprint to have a poor prognosis or (B) by Oncotype Dx to have a high recurrence rate. Screened patients were then further stratified based on that BACH1 gene signature. BACH1+ patients shown in red and BACH1- patients shown in black on both plots.





    • Further patient stratification over existing signatures
    • Specific to TNBC patients



    • Oncology precision medicine
    • Clinical trial enrollment




    • US: 14/952,265



    Reference ID

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.